<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00569244</url>
  </required_header>
  <id_info>
    <org_study_id>91587</org_study_id>
    <secondary_id>2006-004899-13</secondary_id>
    <secondary_id>310882</secondary_id>
    <nct_id>NCT00569244</nct_id>
  </id_info>
  <brief_title>SH T00186 in the Treatment of Primary Dysmenorrhea</brief_title>
  <official_title>A Multi-center, Open-label, Randomized, Controlled, Parallel-group Study to Assess Efficacy and Safety of an Extended Flexible Regimen of the Combined Oral Contraceptive SH T00186D (0.02 mg Ethinylestradiol as Beta-cyclodextrin Clathrate and 3 mg Drospirenone) Compared to the Conventional Regimen of SH T00186D in the Treatment of Primary Dysmenorrhea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigational drug SH T00186D is an oral contraceptive. The investigational drug used
      in this study contains the estrogen ethinylestradiol (EE) and the progestogen drospirenone
      (DRSP).

      The aim of the present study is to evaluate efficacy and safety of the investigational drug
      in the treatment of menstrual pain (pelvic pain occurring shortly before, at onset, during
      menstruation). Two different regimens of intake of the same investigational product will be
      compared.

      Patients have to undergo 2 -3 Baseline cycles (depending on whether the patient was an OC
      user before), during which menstrual pain, bleeding events, and pain killer intake have to be
      documented. During this observation period, the intake of hormonal contraceptives is not
      allowed. Other contraceptive methods (condoms with spermicide, pessary with spermicide) have
      to be used. If the patient is eligible for the study, she will be randomly assigned to one of
      the two treatment groups. Treatment group A will take the medication according to an extended
      flexible regimen, i.e., tablet intake will be triggered by bleeding events. Treatment group B
      will take the study medication in the 24 + 4 days regimen. That means, tablets to be taken on
      cycle days 1 - 24 contain the hormone combination, whereas tablets 25 - 28 do not contain any
      active ingredients, i.e., these are so called placebo tablets.

      Treatment will last at least 140 days, but can be prolonged in Treatment Group A depending of
      occurrence of menstrual bleeding. The overall study duration will be 10 months for each
      patient.

      During the whole study period, 5 visits are planned. At Screening and Final examination, a
      thorough physical examination and a gynecological examination (including breath palpation and
      cervical smear ) will be performed. Blood samples will be taken for safety laboratory
      parameters.

      Additional examinations can be performed any time, if this becomes necessary for medical
      reasons.

      Patients will be provided with a patient diary to document the intake of study medication,
      any bleeding events and days without bleeding, pregnancy test results, any dysmenorrheic
      (menstrual) pain and its intensity and its interference with daily activity, and intake of
      pain medication. The pain medication (ibuprofen) will be provided.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of days with dysmenorrheic pain</measure>
    <time_frame>140 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Use of rescue medication</measure>
    <time_frame>140 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interference with daily activity</measure>
    <time_frame>140 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days: with at least moderate dysmenorrheic pain</measure>
    <time_frame>140 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days with pelvic pain</measure>
    <time_frame>140 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days with dysmenorrheic pain associated with withdrawal bleeding</measure>
    <time_frame>140 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days with dysmenorrheic pain associated with unscheduled bleeding</measure>
    <time_frame>140 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding patterns</measure>
    <time_frame>Whole treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of treatment</measure>
    <time_frame>Whole treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">223</enrollment>
  <condition>Primary Dysmenorrhea</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: YAZ flex (SH T00186D)</intervention_name>
    <description>Extended flexible regimen of YAZ (SH T00186D); triggered by bleeding events(Tablet p.o. (oral))</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YAZ (SH T00186D)</intervention_name>
    <description>YAZ (SH T 00186D) administered in the conventional regimen (24 days active + 4 days placebo) (Tablet p.o. (oral))</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Otherwise healthy female patients with moderate to severe primary dysmenorrhea

          -  Prospective self-rated sum pain score of &gt;/= 8 during the 2 baseline cycles

          -  Age between 18 and 40 years (inclusive) with smoking habits as follows:

               -  between 18 and 30 years of age. daily cigarette consumption not above 10

               -  above 30 years of age, no smoking

        Exclusion Criteria:

          -  Current signs of history of any forms of secondary dysmenorrhea

          -  Any concomitant disease of condition that requires any intake of analgesic medication

          -  Occurrence of less than six menstrual cycles before Visit 1 following delivery,
             abortion, or lactation

          -  Clinically significant depression
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nürnberg</city>
        <state>Bayern</state>
        <zip>90491</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60439</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fulda</city>
        <state>Hessen</state>
        <zip>36037</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mühlheim</city>
        <state>Hessen</state>
        <zip>63165</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30459</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bernburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>06406</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Blankenburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>38889</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39288</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jessen</city>
        <state>Sachsen-Anhalt</state>
        <zip>06917</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39130</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04207</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04277</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04299</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wurzen</city>
        <state>Sachsen</state>
        <zip>04808</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gera</city>
        <state>Thüringen</state>
        <zip>07545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kahla</city>
        <state>Thüringen</state>
        <zip>07768</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10247</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10409</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>12587</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13086</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chesterfield</city>
        <state>Derbyshire</state>
        <zip>S40 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>Tyne and Wear</state>
        <zip>NE4 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <link>
    <url>http://www.clinicaltrialsregister.eu</url>
    <description>Click here and search for information of Bayer products for Europe</description>
  </link>
  <results_reference>
    <citation>Strowitzki T, Kirsch B, Elliesen J. Efficacy of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen in women with moderate-to-severe primary dysmenorrhoea: an open-label, multicentre, randomised, controlled study. J Fam Plann Reprod Health Care. 2012 Apr;38(2):94-101. doi: 10.1136/jfprhc-2011-100225.</citation>
    <PMID>22454006</PMID>
  </results_reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2007</study_first_submitted>
  <study_first_submitted_qc>December 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2007</study_first_posted>
  <last_update_submitted>October 28, 2014</last_update_submitted>
  <last_update_submitted_qc>October 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Dysmenorrhea</keyword>
  <keyword>Menstrual Pain</keyword>
  <keyword>Oral Contraception</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysmenorrhea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

